APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of alzheimer disease

Journal of Biological Chemistry

Volumn 287, Issue 50, 2012, Pages 41774-41786

  Youmans, Katherine L ^a,h   Tai, Leon M ^a   Nwabuisi Heath, Evelyn ^a   Jungbauer, Lisa ^a,i   Kanekiyo, Takahisa ^b   Gan, Ming ^b   Kim, Jungsu ^c   Eimer, William A ^d   Estus, Steve ^e   Rebeck, G William ^f   Weeber, Edwin J ^g   Bu, Guojun ^b   Yu, Chunjiang ^a   LaDu, Mary Jo ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

^h BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MEDTRONIC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AMYLOID DEPOSITION; IN-VIVO; ISOFORMS; PLAQUE MORPHOLOGY; RISK FACTORS; SYNERGISTIC EFFECT; TRANSGENIC MICE;

FORMIC ACID; GLYCOPROTEINS; NEURODEGENERATIVE DISEASES; OLIGOMERS;

MAMMALS;

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; DISEASE MODEL; EXTRACTION AND EXTRACTS; FRONTAL CORTEX; GENOTYPE; HIPPOCAMPUS; MALE; MORPHOLOGY; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN LOCALIZATION; SUBICULUM; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEIN E4; DISEASE MODELS, ANIMAL; GENOTYPE; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; PROTEIN ISOFORMS;

MUS; MUS MUSCULUS;

EID: 84871268485     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.407957     Document Type: Article

References (90)

1. Bu, G. (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333-344
2. Kim, J., Jiang, H., Park, S., Eltorai, A. E., Stewart, F. R., Yoon, H., Basak, J. M., Finn, M. B., and Holtzman, D. M. (2011) Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J. Neurosci. 31, 18007-18012
3. Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., Hansen, J. C., Sullivan, P. M., and Paul, S. M. (2009) Human APOE isoform-dependent effects on brain β-amyloid levels in PDAPP transgenic mice. J. Neurosci. 29, 6771-6779
4. Drzezga, A., Grimmer, T., Henriksen, G., Mühlau, M., Perneczky, R., Miederer, I., Praus, C., Sorg, C., Wohlschläger, A., Riemenschneider, M., Wester, H. J., Foerstl, H., Schwaiger, M., and Kurz, A. (2009) Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72, 1487-1494
5. Grimmer, T., Tholen, S., Yousefi, B. H., Alexopoulos, P., Förschler, A., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Perneczky, R., Sorg, C., Kurz, A., and Drzezga, A. (2010) Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease. Biol. Psychiatry 68, 879-884
6. Buttini, M., Yu, G. Q., Shockley, K., Huang, Y., Jones, B., Masliah, E., Mallory, M., Yeo, T., Longo, F. M., and Mucke, L. (2002) Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid β peptides but not on plaque formation. J. Neurosci. 22, 10539-10548 (Pubitemid 36005128)
7. Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., and Paul, S. M. (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 97, 2892-2897 (Pubitemid 30159268)
8. Fryer, J. D., Simmons, K., Parsadanian, M., Bales, K. R., Paul, S. M., Sullivan, P. M., and Holtzman, D. M. (2005) Human apolipoprotein E4 alters the amyloid-β 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 25, 2803-2810 (Pubitemid 40389238)
9. Sullivan, P. M., Mezdour, H., Aratani, Y., Knouff, C., Najib, J., Reddick, R. L., Quarfordt, S. H., and Maeda, N. (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 272, 17972-17980 (Pubitemid 27306374)
10. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., Guido, T., Hagopian, S., Johnson-Wood, K., Khan, K., Lee, M., Leibowitz, P., Lieberburg, I., Little, S., Masliah, E., McConlogue, L., Montoya-Zavala, Mucke, L., Paganini, L., Penniman, E., Power, M., Schenk, D., Seubert, P., Snyder, B., Soriano, F., Tan, H., Vitale, J., Wadsworth, S., Wolozin, B., and Zhao, J. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373, 523-527
11. Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., Berry, R., and Vassar, R. (2006) Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129-10140 (Pubitemid 44527407)
12. Fernández-Vizarra, P., Fernández, A. P., Castro-Blanco, S., Serrano, J., Bentura, M. L., Martínez-Murillo, R., Martínez, A., and Rodrigo, J. (2004) Intra- and extracellular Aβ and PHF in clinically evaluated cases of Alzheimer's disease. Histol. Histopathol. 19, 823-844 (Pubitemid 38855065)
13. D'Andrea, M. R., Nagele, R. G., Wang, H. Y., and Lee, D. H. (2002) Consistent immunohistochemical detection of intracellular β-amyloid42 in pyramidal neurons of Alzheimer's disease entorhinal cortex. Neurosci. Lett. 333, 163-166 (Pubitemid 35335768)
14. D'Andrea, M. R., Nagele, R. G., Wang, H. Y., Peterson, P. A., and Lee, D. H. (2001) Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 38, 120-134 (Pubitemid 32193626)
15. Thal, D. R., Griffin, W. S., and Braak, H. (2008) Parenchymal and vascular Aβ-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J. Cell. Mol. Med. 12, 1848-1862
16. Thal, D. R., Capetillo-Zarate, E., Del Tredici, K., and Braak, H. (2006) The development of amyloid β protein deposits in the aged brain. Sci. Aging Knowledge Environ. 2006, re1
17. Haass, C., and Selkoe, D. J. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112 (Pubitemid 46432529)
18. Kuo, Y. M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., and Roher, A. E. (1996) Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271, 4077-4081
19. Selkoe, D. J. (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 17, 1060-1065
20. Tomic, J. L., Pensalfini, A., Head, E., and Glabe, C. G. (2009) Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol. Dis. 35, 352-358
21. Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., and Selkoe, D. J. (2011) Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. U.S.A. 108, 5819-5824
22. McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., Bush, A. I., and Masters, C. L. (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866
23. Huang, Y., and Mucke, L. (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222
24. Xia, W., Yang, T., Shankar, G., Smith, I. M., Shen, Y., Walsh, D. M., and Selkoe, D. J. (2009) A specific enzyme-linked immunosorbent assay for measuring β-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch. Neurol. 66, 190-199
25. Youmans, K. L., Tai, L. M., Kanekiyo, T., Stine, W. B., Jr., Michon, S. C., Nwabuisi-Heath, E., Manelli, A. M., Fu, Y., Riordan, S., Eimer, W. A., Binder, L., Bu, G., Yu, C., Hartley, D. M., and LaDu, M. J. (2012) Intraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody. Mol. Neurodegener. 7, 8
26. Poirier, J. (2005) Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol. Aging 26, 355-361
27. Poirier, J. (2008) Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer's disease. Alzheimers Dement. 4, S91-S97
28. Ramaswamy, G., Xu, Q., Huang, Y., and Weisgraber, K. H. (2005) Effect of domain interaction on apolipoprotein E levels in mouse brain. J. Neurosci. 25, 10658-10663 (Pubitemid 41681913)
29. Raffai, R. L., Dong, L. M., Farese, R. V., Jr., and Weisgraber, K. H. (2001) Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. Proc. Natl. Acad. Sci. U.S.A. 98, 11587-11591 (Pubitemid 32928772)
30. Bertrand, P., Poirier, J., Oda, T., Finch, C. E., and Pasinetti, G. M. (1995) Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res. Mol. Brain Res. 33, 174-178
31. Glöckner, F., Meske, V., and Ohm, T. G. (2002) Genotype-related differences of hippocampal apolipoprotein E levels only in early stages of neuropathological changes in Alzheimer's disease. Neuroscience 114, 1103-1114
32. Cruchaga, C., Kauwe, J. S., Nowotny, P., Bales, K., Pickering, E. H., Mayo, K., Bertelsen, S., Hinrichs, A., The Alzheimer's Disease Neuroimaging Initiative, Fagan, A. M., Holtzman, D. M., Morris, J. C., and Goate, A. M. (2012) Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Hum. Mol. Genet. 21, 4558-4571
33. Beffert, U., Cohn, J. S., Petit-Turcotte, C., Tremblay, M., Aumont, N., Ramassamy, C., Davignon, J., and Poirier, J. (1999) Apolipoprotein E and β-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype-dependent. Brain Res. 843, 87-94 (Pubitemid 29488698)
34. Sullivan, P. M., Han, B., Liu, F., Mace, B. E., Ervin, J. F., Wu, S., Koger, D., Paul, S., and Bales, K. R. (2011) Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol. Aging 32, 791-801
35. Riddell, D. R., Zhou, H., Atchison, K., Warwick, H. K., Atkinson, P. J., Jefferson, J., Xu, L., Aschmies, S., Kirksey, Y., Hu, Y., Wagner, E., Parratt, A., Xu, J., Li, Z., Zaleska, M. M., Jacobsen, J. S., Pangalos, M. N., and Reinhart, P. H. (2008) Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J. Neurosci. 28, 11445-11453 18987181
36. Cushley, R. J., and Okon, M. (2002) NMR studies of lipoprotein structure. Annu. Rev. Biophys. Biomol. Struct. 31, 177-206 (Pubitemid 34666830)
37. Gangabadage, C. S., Zdunek, J., Tessari, M., Nilsson, S., Olivecrona, G., and Wijmenga, S. S. (2008) Structure and dynamics of human apolipoprotein CIII. J. Biol. Chem. 283, 17416-17427
38. Krul, E. S., and Cole, T. G. (1996) Quantitation of apolipoprotein E. Methods Enzymol. 263, 170-187 (Pubitemid 126691170)
39. Jones, P. B., Adams, K. W., Rozkalne, A., Spires-Jones, T. L., Hshieh, T. T., Hashimoto, T., von Armin, C. A., Mielke, M., Bacskai, B. J., and Hyman, B. T. (2011) Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-β in human Alzheimer brain. PLoS One 6, e14586
40. Hawkes, C. A., Sullivan, P. M., Hands, S., Weller, R. O., Nicoll, J. A., and Carare, R. O. (2012) Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 allele. PLoS One 7, e41636
41. Wang, N., Weng, W., Breslow, J. L., and Tall, A. R. (1996) Scavenger receptor BI (SR-BI) is up-regulated in adrenal gland in apolipoprotein A-I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores. In vivo evidence that SR-BI is a functional high density lipoprotein receptor under feedback control. J. Biol. Chem. 271, 21001-21004 (Pubitemid 26292944)
42. Youmans, K. L., Leung, S., Zhang, J., Maus, E., Baysac, K., Bu, G., Vassar, R., Yu, C., and LaDu, M. J. (2011) Amyloid-β42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations. J. Neurosci. Methods 196, 51-59
43. Sullivan, P. M., Mezdour, H., Quarfordt, S. H., and Maeda, N. (1998) Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J. Clin. Invest. 102, 130-135 (Pubitemid 28323839)
44. Tai, L. M., Youmans, K. L., Jungbauer, L., Yu, C., and LaDu, M. J. (2011) Introducing human APOE into Aβ transgenic mouse models. Int. J. Alzheimers Dis. 2011, 810981
45. Bien-Ly, N., Gillespie, A. K., Walker, D., Yoon, S. Y., and Huang, Y. (2012) Reducing human apolipoprotein E levels attenuates age-dependent Aβ accumulation in mutant human amyloid precursor protein transgenic mice. J. Neurosci. 32, 4803-4811
46. Moore, B. D., Rangachari, V., Tay, W. M., Milkovic, N. M., and Rosenberry, T. L. (2009) Biophysical analyses of synthetic amyloid-β(1-42) aggregates before and after covalent cross-linking. Implications for deducing the structure of endogenous amyloid-β oligomers. Biochemistry 48, 11796-11806
47. Dahlgren, K. N., Manelli, A. M., Stine, W. B., Jr., Baker, L. K., Krafft, G. A., and LaDu, M. J. (2002) Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 277, 32046-32053 (Pubitemid 34969015)
48. Stine, W. B., Jr., Dahlgren, K. N., Krafft, G. A., and LaDu, M. J. (2003) In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis. J. Biol. Chem. 278, 11612-11622 (Pubitemid 36792723)
49. Kim, D., and Tsai, L. H. (2009) Bridging physiology and pathology in AD. Cell 137, 997-1000
50. Fiala, J. C. (2007) Mechanisms of amyloid plaque pathogenesis. Acta Neuropathol. 114, 551-571
51. West, M. J., Slomianka, L., and Gundersen, H. J. (1991) Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231, 482-497
52. Larson, M. E., and Lesné, S. E. (2012) Soluble Aβ oligomer production and toxicity. J. Neurochem. 120, Suppl. 1, 125-139
53. Verghese, P. B., Castellano, J. M., and Holtzman, D. M. (2011) Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 10, 241-252
54. Berlau, D. J., Corrada, M. M., Head, E., and Kawas, C. H. (2009) APOE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology 72, 829-834
55. Berlau, D. J., Kahle-Wrobleski, K., Head, E., Goodus, M., Kim, R., and Kawas, C. (2007) Dissociation of neuropathologic findings and cognition: case report of an apolipoprotein E ε2/ε2 genotype. Arch. Neurol. 64, 1193-1196 (Pubitemid 47258081)
56. Gouras, G. K., Tampellini, D., Takahashi, R. H., and Capetillo-Zarate, E. (2010) Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol. 119, 523-541
57. Bayer, T. A., and Wirths, O. (2010) Intracellular accumulation of amyloid-β: a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. Front. Aging Neurosci. 2, 8
58. Sullivan, P. M., Mace, B. E., Maeda, N., and Schmechel, D. E. (2004) Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience 124, 725-733 (Pubitemid 38328762)
59. Vitek, M. P., Brown, C. M., and Colton, C. A. (2009) APOE genotype-specific differences in the innate immune response. Neurobiol. Aging 30, 1350-1360
60. Koffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., Hyman, B. T., and Spires-Jones, T. L. (2009) Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. U.S.A. 106, 4012-4017
61. Spires-Jones, T. L., de Calignon, A., Meyer-Luehmann, M., Bacskai, B. J., and Hyman, B. T. (2011) Monitoring protein aggregation and toxicity in Alzheimer's disease mouse models using in vivo imaging. Methods 53, 201-207
62. Winton, M. J., Lee, E. B., Sun, E., Wong, M. M., Leight, S., Zhang, B., Trojanowski, J. Q., and Lee, V. M. (2011) Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for Tau versus Aβ-mediated Alzheimer neurodegeneration. J. Neurosci. 31, 7691-7699
63. Christensen, D. Z., Schneider-Axmann, T., Lucassen, P. J., Bayer, T. A., and Wirths, O. (2010) Accumulation of intraneuronal Aβ correlates with ApoE4 genotype. Acta Neuropathol. 119, 555-566
64. Jiang, Q., Lee, C. Y., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., Richardson, J. C., Smith, J. D., Comery, T. A., Riddell, D., Holtzman, D. M., Tontonoz, P., and Landreth, G. E. (2008) ApoE promotes the proteolytic degradation of Aβ. Neuron 58, 681-693
65. Hirsch-Reinshagen, V., Maia, L. F., Burgess, B. L., Blain, J. F., Naus, K. E., McIsaac, S. A., Parkinson, P. F., Chan, J. Y., Tansley, G. H., Hayden, M. R., Poirier, J., Van Nostrand, W., and Wellington, C. L. (2005) The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer's disease. J. Biol. Chem. 280, 43243-43256 (Pubitemid 43049291)
66. LaDu, M. J., Falduto, M. T., Manelli, A. M., Reardon, C. A., Getz, G. S., and Frail, D. E. (1994) Isoform-specific binding of apolipoprotein E to β-amyloid. J. Biol. Chem. 269, 23403-23406
67. LaDu, M. J., Lukens, J. R., Reardon, C. A., and Getz, G. S. (1997) Association of human, rat, and rabbit apolipoprotein E with β-amyloid. J. Neurosci. Res. 49, 9-18 (Pubitemid 27291172)
68. LaDu, M. J., Munson, G. W., Jungbauer, L., Getz, G. S., Reardon, C. A., Tai, L. M., and Yu, C. (2012) Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift. Biochim. Biophys. Acta 1821, 295-302
69. LaDu, M. J., Stine, W. B., Jr., Narita, M., Getz, G. S., Reardon, C. A., and Bu, G. (2006) Self-assembly of HEK cell-secreted ApoE particles resembles ApoE enrichment of lipoproteins as a ligand for the LDL receptor-related protein. Biochemistry 45, 381-390 (Pubitemid 43100405)
70. Manelli, A. M., Stine, W. B., Van Eldik, L. J., and LaDu, M. J. (2004) ApoE and Aβ1-42 interactions: effects of isoform and conformation on structure and function. J. Mol. Neurosci. 23, 235-246
71. Holtzman, D. M., Herz, J., and Bu, G. (2012) Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006312
72. Hauser, P. S., Narayanaswami, V., and Ryan, R. O. (2011) Apolipoprotein E: from lipid transport to neurobiology. Prog. Lipid Res. 50, 62-74
73. Gong, J. S., Kobayashi, M., Hayashi, H., Zou, K., Sawamura, N., Fujita, S. C., Yanagisawa, K., and Michikawa, M. (2002) Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J. Biol. Chem. 277, 29919-29926
74. Wang, H., Durham, L., Dawson, H., Song, P., Warner, D. S., Sullivan, P. M., Vitek, M. P., and Laskowitz, D. T. (2007) An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction. Neuroscience 144, 1324-1333 (Pubitemid 46123809)
75. Sadowski, M. J., Pankiewicz, J., Scholtzova, H., Mehta, P. D., Prelli, F., Quartermain, D., and Wisniewski, T. (2006) Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 103, 18787-18792 (Pubitemid 44913488)
76. Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., Brunden, K. R., Wilson, D. A., and Landreth, G. E. (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335, 1503-1506
77. Mahley, R. W., Weisgraber, K. H., and Huang, Y. (2006) Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 103, 5644-5651
78. Trommer, B. L., Shah, C., Yun, S. H., Gamkrelidze, G., Pasternak, E. S., Stine, W. B., Manelli, A., Sullivan, P., Pasternak, J. F., and LaDu, M. J. (2005) ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-β1-42. Neurobiol. Dis. 18, 75-82 (Pubitemid 40092897)
79. Manelli, A. M., Bulfinch, L. C., Sullivan, P. M., and LaDu, M. J. (2007)Aβ42 neurotoxicity in primary co-cultures: effect of apoE isoform and Aβ conformation. Neurobiol. Aging 28, 1139-1147 (Pubitemid 46810054)
80. Cerf, E., Gustot, A., Goormaghtigh, E., Ruysschaert, J. M., and Raussens, V. (2011) High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease. FASEB J. 25, 1585-1595
81. Petrlova, J., Hong, H. S., Bricarello, D. A., Harishchandra, G., Lorigan, G. A., Jin, L. W., and Voss, J. C. (2011) A differential association of Apolipoprotein E isoforms with the amyloid-β oligomer in solution. Proteins 79, 402-416
82. Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., Higgs, R., Liu, F., Malkani, S., Bales, K. R., and Paul, S. M. (2004) Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides. Nat. Med. 10, 719-726 (Pubitemid 38937637)
83. Mandrekar, S., Jiang, Q., Lee, C. Y., Koenigsknecht-Talboo, J., Holtzman, D. M., and Landreth, G. E. (2009) Microglia mediate the clearance of soluble Aβ through fluid phase macropinocytosis. J. Neurosci. 29, 4252-4262
84. Basak, J. M., Verghese, P. B., Yoon, H., Kim, J., and Holtzman, D. M. (2012) Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Aβ uptake and degradation by astrocytes. J. Biol. Chem. 287, 13959-13971
85. Thal, D. R. (2012) The role of astrocytes in amyloid β-protein toxicity and clearance. Exp. Neurol. 236, 1-5
86. Vekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D., Hartley, D., Chesneau, V., Rosner, M. R., and Selkoe, D. J. (2000) Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20, 1657-1665 (Pubitemid 30220363)
87. Wirths, O., and Bayer, T. A. (2012) Intraneuronal Aβ accumulation and neurodegeneration: lessons from transgenic models. Life Sci. 91, 1148-1152
88. Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., and Zlokovic, B. V. (2008) apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. J. Clin. Invest. 118, 4002-4013
89. Bachmeier, C., Beaulieu-Abdelahad, D., Crawford, F., Mullan, M., and Paris, D. (2012) Stimulation of the retinoid X receptor facilitates β-amyloid clearance across the blood-brain barrier. J. Mol. Neurosci., in press
90. Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., Goate, A. M., Bales, K. R., Paul, S. M., Bateman, R. J., and Holtzman, D. M. (2011) Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 3, 89ra57